Nawa A - Search Results

1

Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.

Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR, Hamaguchi M. Thant AA, et al. Among authors: nawa a. Clin Exp Metastasis. 2000;18(5):423-8. doi: 10.1023/a:1010921730952. Clin Exp Metastasis. 2000. PMID: 11467775

2

Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue.

Shibata K, Kikkawa F, Nawa A, Tamakoshi K, Suganuma N, Tomoda Y. Shibata K, et al. Among authors: nawa a. Clin Exp Metastasis. 1997 Nov;15(6):612-9. doi: 10.1023/a:1018495414975. Clin Exp Metastasis. 1997. PMID: 9344045

3

Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines.

Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M. Shibata K, et al. Among authors: nawa a. Cancer Res. 1997 Dec 1;57(23):5416-20. Cancer Res. 1997. PMID: 9393769

4

Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells.

Shibata K, Kikkawa F, Nawa A, Thant AA, Naruse K, Mizutani S, Hamaguchi M. Shibata K, et al. Among authors: nawa a. Cancer Res. 1998 Mar 1;58(5):900-3. Cancer Res. 1998. PMID: 9500447

5

The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1.

Liu E, Thant AA, Kikkawa F, Kurata H, Tanaka S, Nawa A, Mizutani S, Matsuda S, Hanafusa H, Hamaguchi M. Liu E, et al. Among authors: nawa a. Cancer Res. 2000 May 1;60(9):2361-4. Cancer Res. 2000. PMID: 10811109

6

Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues.

Kikkawa F, Tamakoshi K, Nawa A, Shibata K, Yamagata S, Yamagata T, Suganuma N. Kikkawa F, et al. Among authors: nawa a. Cancer Lett. 1997 Nov 25;120(1):109-15. doi: 10.1016/s0304-3835(97)00295-4. Cancer Lett. 1997. PMID: 9570393

7

Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon beta.

Kato N, Nawa A, Tamakoshi K, Kikkawa F, Suganuma N, Okamoto T, Goto S, Tomoda Y, Hamaguchi M, Nakajima M. Kato N, et al. Among authors: nawa a. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):601-6. doi: 10.1016/0002-9378(95)90579-0. Am J Obstet Gynecol. 1995. PMID: 7856692

8

The different stimulatory effect of normal tissues on the secretion of matrix metalloproteinases and their inhibitors by human ovarian cancer cells.

Kikkawa F, Nawa A, Shibata K, Obata NH, Tamakoshi K, Suzuki S, Mizutani S. Kikkawa F, et al. Among authors: nawa a. Anticancer Res. 1998 Nov-Dec;18(6A):4323-8. Anticancer Res. 1998. PMID: 9891486

9

Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form.

Tamakoshi K, Kikkawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N, Tomoda Y. Tamakoshi K, et al. Among authors: nawa a. Cancer. 1995 Dec 15;76(12):2565-71. doi: 10.1002/1097-0142(19951215)76:12<2565::aid-cncr2820761224>3.0.co;2-b. Cancer. 1995. PMID: 8625086

10

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro.

Wakahara Y, Nawa A, Okamoto T, Hayakawa A, Kikkawa F, Suganama N, Wakahara F, Tomoda Y. Wakahara Y, et al. Among authors: nawa a. Oncology. 1997 Jan-Feb;54(1):48-54. doi: 10.1159/000227661. Oncology. 1997. PMID: 8978593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters